Clinically significant prostate cancer was detected in 2.3% of men (119 of 5134) in the biomarker group (Stockholm3 risk score ≥0.15%) and in 2.5% of men (192 of 7609) in the MRI-enhanced group (PSA level ≥3 ng/mL), for a relative proportion of 0.92 (95% CI, 0.73-1.15). Here, KLK3 is linked to prostate carcinoma.